Recent Updates
Recently added Catalysts
NM

NeuroOne Medical Technologies Corporation

NMTCFDA catalysts, PDUFA dates & pipeline intelligence
$0.78
▲ +0.03 · +4.51%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full NMTC financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.7452W HIGH $6.12
Volume
4.11 K
Value Traded
3.23 K
Short % Float
2.86%
Days to Cover
2.4
+0.19%Week
-22.14%1 Month
-58.59%3 Month
-81.06%6 Month
-90.36%5 Year
+2.5%All Time

Cash Data

Unlock NMTC cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
7.09 M
EPS (TTM)
-0.82
P/E Ratio
-
Ent. Value
5.15 M
Total Shares
9.11 M
Float Shares
7.25 M
Insiders
20.39%
Institutions
25.27%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every NMTC catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

NMTC Catalyst Timeline

Dated clinical, regulatory and corporate events for NeuroOne Medical Technologies Corporation

Unlock the full NMTC catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How NMTC actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all NMTC historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

No drug pipeline

NeuroOne Medical Technologies Corporation is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.

Clinical Trial Results

Readouts, endpoints and source filings for every NMTC program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every NMTC trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock NMTC insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Wambeke David J.Officer (Chief Business Officer)Buy 33,333 199,999 held$2.01 08/27/2026
Unlock the full NMTC insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in NMTC for Q3 2026.
Unlock every fund holding NMTC
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in NMTC
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see NMTC ownership
Insider and institutional ownership, quarter by quarter.

NMTC Short Interest

Shares sold short, counted twice a month.

2.86%
Short % of Float
of tradable shares sold short
207.1K
Shares Sold Short
-0.1% vs prior count
2.4 Moderate
Days to Cover
trading days of normal volume to buy every short share back
86.8K
Avg Daily Volume
the average used for days to cover
Unlock NMTC short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock NMTC option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live NMTC option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock NMTC options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How NMTC ranks across every disease it competes in

Competitive Position is a premium feature
See how NMTC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

NMTC News

-NMTC
Oct 29, 2026
NMTCPhases
▲ +13%on this news

NeuroOne® Announces Peer-Reviewed Publication of Initial Clinical Experience with OneRF® Trigeminal Nerve Ablation System

NeuroOne Medical Technologies announced positive initial clinical results for its OneRF Trigeminal Nerve Ablation System. A study published in Pain Management showed immediate pain freedom in 14 of 15 patients, with all achieving favorable outcomes at six months. The innovative multi-contact probe technology allowed effective mapping without repositioning, enhancing patient comfort.

Read more →
-NMTC
Oct 27, 2026
NMTCGeneral
▲ +5.7%on this newsshared move

NeuroOne Featured in New York Post on OneRF® Patient’s Remarkable Journey to Overcome Debilitating Facial Pain

NeuroOne Medical Technologies highlighted a feature in the New York Post about Natisha Long, who found relief from trigeminal neuralgia after using the OneRF Trigeminal Nerve Ablation System. This FDA-cleared system allowed her to undergo a minimally invasive procedure, resulting in immediate pain relief. The company aims to expand access to this innovative treatment.

Read more →
-NMTC
Oct 22, 2026
NMTCGeneral
▲ +7.5%on this newsshared move

NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical Company's Research Program

NeuroOne Medical Technologies announced a significant milestone by securing its first pharmaceutical industry purchase order for the StereoCED™ Drug Delivery Platform. This order supports a preclinical research program for a Tier 1 global pharmaceutical company, expected to begin in large animals next year. The platform's unique capabilities may enhance drug development processes.

Read more →
-NMTC
Oct 8, 2026
NMTCGeneral

NeuroOne® Joins Dartmouth-Led Research Team on $1 Million NIH Grant to Advance Neurotransmitter Sensing Technology

NeuroOne Medical Technologies has partnered with Dartmouth College on a $1 million NIH grant to develop advanced neurotransmitter sensing technology. The initial funding of approximately $200,000 will support research through April 2027. This collaboration aims to enhance real-time monitoring of brain activity and neurochemical signaling, potentially improving treatment for neurological disorders.

Read more →
-NMTC
Oct 5, 2026
NMTCGeneral

NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order

NeuroOne Medical Technologies reported preliminary fiscal Q4 2026 product revenue of $3.8 million, marking a 38.4% increase from the previous year. The company also announced a record purchase order of $4.5 million, contributing to total open orders of $5.4 million. Full-year revenue is expected to reach $10.5 million, reflecting a 15.6% growth.

Read more →
-NMTC
Sep 17, 2026
NMTCGeneral

NeuroOne® Expands U.S. Commercialization of FDA-Cleared OneRF® Trigeminal Nerve Ablation System with New Southern California Distribution Agreement

NeuroOne Medical Technologies Corporation announced a new distribution agreement for its FDA-cleared OneRF® Trigeminal Nerve Ablation System in Southern California. This agreement aims to enhance commercial access in a key market, supporting the company's strategy to expand its distribution network. The OneRF® system offers a less invasive treatment option for patients suffering from trigeminal neuralgia.

Read more →
-NMTC
May 22, 2026
NMTCGeneral
▼ -5.4%on this news

NeuroOne Medical Technologies Announces Restatement of Financial Results for Quarter Ending March 31, 2026 Ongoing Business Not Affected, Company Reaffirms

NeuroOne Medical Technologies Corporation has announced a restatement of its financial results for the quarter ending March 31, 2026, due to a revenue overstatement caused by customer order modifications. The company confirmed that this restatement will not impact its product revenue guidance for fiscal year 2026, which remains at least $10.5 million. Despite the need for correction, NeuroOne's ongoing business operations and growth strategies are reported to be stable. The company intends to amend its financial statements and improve internal controls over financial reporting.

Read more →
-NMTC
May 12, 2026
NMTCGeneral

NeuroOne Reports Fiscal Q2 2026 Financial Results and Provides Corporate Business Update

NeuroOne Medical Technologies Corporation has reported financial results for Q2 2026, showing a remarkable 72% increase in product revenue amounting to $2.4 million. The company successfully completed 16 trigeminal neuralgia procedures, with all patients reportedly pain-free. While operational expenses remained consistent, the quarterly net loss decreased slightly when compared year-on-year. The report also highlights future growth prospects with the continued expansion of its product lines and international market reach.

Read more →
-NMTC
Feb 17, 2026
NMTCGeneral
▼ -16.5%on this news

NeuroOne Reports Fiscal Q1 2026 Financial Results; Expects

NeuroOne Medical Technologies Corporation reported its financial results for the first quarter of fiscal 2026, highlighting product revenue expectations of at least $10.5 million. During this quarter, nearly half of all ablations using the OneRF Ablation System since its launch were completed. The company successfully concluded nine cases for trigeminal neuralgia, with all patients reporting pain relief. However, product revenues faced a slight decline from the previous year, and the company recorded a net loss during this period.

Read more →
-NMTC
Dec 22, 2025
NMTCGeneral
▲ +9.5%on this news

NeuroOne Appoints Jason Mills to the Board of Directors Med-Tech Research Analyst & Public Company Executive to Bring Strategic Experience, Industry Relationships and Vision to the Board

NeuroOne Medical Technologies Corporation has appointed Jason Mills to its Board of Directors, effective December 18, 2025. Mills brings over two decades of experience in med-tech investment analysis and currently serves as Executive Vice President of Strategy at Penumbra, Inc. His extensive background, including awards for his equity research, is expected to provide valuable insights as NeuroOne progresses with its clinical and corporate goals. The appointment is seen as a strategic move to enhance the company's value in transforming the diagnosis and treatment of neurological disorders.

Read more →
-NMTC
Dec 17, 2025
NMTCGeneral
▼ -5.5%on this newsshared move

NeuroOne Reports Strong Fourth Quarter Fiscal 2025 Financial Results with Product Revenue Growth of 907% to $2.7 Million and 55.8% Gross Margin

NeuroOne Medical Technologies Corporation announced its fiscal 2025 financial results, showcasing robust growth. The company achieved a remarkable 907% increase in product revenue in the fourth quarter, reaching $2.7 million, and a total revenue increase of 163% for the fiscal year, totaling $9.1 million. Contributing to this success was the strong performance of the OneRF Ablation System, alongside achieving FDA 510(k) clearance for the OneRF Trigeminal Nerve Ablation System. The balance sheet also strengthened, positioning the company for further expansion and development in 2026.

Read more →
-NMTC
Oct 6, 2025
NMTCConferences/Events
▲ +7.1%on this news

NeuroOne Announces Preliminary Unaudited Product

NeuroOne Medical Technologies Corporation has reported a significant preliminary unaudited product revenue growth of 163%, reaching a record $9.1 million for the fiscal year ending September 30, 2025. This growth is attributed to increased customer interest and favorable outcomes associated with its OneRF Ablation system for epilepsy patients. The company will provide further financial details in December 2025 and is hosting a virtual investor webinar on October 7, 2025, to discuss recent developments.

Read more →
-NMTC
Sep 8, 2025
NMTCConferences/Events
▲ +5.1%on this news

NeuroOne® to Participate in Sidoti Small-Cap Conference on September 17th and 18th, 2025

NeuroOne Medical Technologies Corporation will participate in the Sidoti Small-Cap Conference on September 17-18, 2025. CEO Dave Rosa and CFO Ron McClurg will present on September 17 and hold one-on-one meetings with investors. The company reported a 105% revenue increase and received FDA clearance for its Trigeminal Nerve Ablation System.

Read more →
-NMTC
Aug 18, 2025
NMTCFDA Updates

NeuroOne® Receives FDA 510(k) Clearance for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain

NeuroOne Medical Technologies has received FDA clearance for its OneRF® Trigeminal Nerve Ablation System, designed to treat trigeminal neuralgia, a chronic facial pain condition. This minimally invasive system utilizes radiofrequency energy to create lesions in the trigeminal nerve, potentially improving patient outcomes. A limited commercial launch is targeted for late 2025.

Read more →
-NMTC
Aug 14, 2025
NMTCGeneral

NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9%

NeuroOne Medical Technologies reported third quarter fiscal 2025 revenue of $1.7 million, a 105 percent increase from the prior year. Gross margin expanded to 53.9 percent during the same period. The company also completed an $8.2 million capital raise to fund operations through at least fiscal year 2026. Operating expenses decreased by 9 percent to $2.8 million compared to the previous year.

Read more →
-NMTC
Jul 31, 2025
NMTCConferences/Events

NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time - Update

NeuroOne Medical Technologies Corporation will release its financial results for the third quarter of fiscal year 2025 on August 14, 2025. The company will also host an investor conference call to discuss these results and provide a corporate update. Interested participants can join the call via provided dial-in information.

Read more →
-NMTC
Jul 23, 2025
NMTCGeneral
▼ -12.8%on this news

NeuroOne® Receives Notice of Allowance for Key Patent from U.S. Patent & Trademark Office

NeuroOne Medical Technologies Corporation has received a notice of allowance for a key patent from the U.S. Patent and Trademark Office. This patent, titled 'Methods for Making Probe Devices and Related Devices,' covers innovative methods for creating neural probe devices. The company expects the patent to be issued soon, enhancing its intellectual property portfolio, which includes 17 patents related to electrode technologies.

Read more →
-NMTC
Jun 23, 2025
NMTCGeneral

NeuroOne® Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF® Ablation System

NeuroOne Medical Technologies Corporation announced that Clara, an early patient treated with the OneRF® Ablation System, has surpassed one year of being seizure-free. This milestone highlights the effectiveness of the device, which is FDA-cleared for both diagnostic and therapeutic use. The company aims to leverage this technology for further applications, including treating facial pain.

Read more →
-NMTC
Jun 3, 2025
NMTCGeneral
▼ -6%on this news

NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary

NeuroOne Medical Technologies Corporation has appointed Emily Johns as General Counsel and Corporate Secretary. This strategic hire is expected to strengthen the management team and reduce legal costs. Johns brings extensive experience in corporate governance and has previously worked with NeuroOne on transactional matters. She expressed excitement about joining the company during a pivotal time.

Read more →
-NMTC
May 29, 2025
NMTCConferences/Events

NeuroOne to Attend MedInvest’s MedTech, AI & Digital Health Conference on June 3-4, 2025

NeuroOne Medical Technologies Corporation will participate in the MedInvest MedTech, AI & Digital Health Conference on June 3-4, 2025, in San Francisco. CEO Dave Rosa will meet with investors during the event, which will include discussions on medical devices and digital health technologies. This participation highlights NeuroOne's commitment to advancing surgical care for neurological disorders.

Read more →

About NeuroOne Medical Technologies Corporation

Eden Prairie, MN 18 employees n1mtc.com
Headquarters7599 ANAGRAM DR, EDEN PRAIRIE, MN, 55344
BIOPHARMAWATCH ELITE
Trade the next NMTC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime